<DOC>
	<DOCNO>NCT00361088</DOCNO>
	<brief_summary>In Phase I , patient receive combination PS-341 ( Velcade ) R115777 ( Zarnestra ) determine dose limit toxicity ( DLT ) . Once DLT determine , patient Phase II receive maximum tolerate dose ( MTD ) complete 8 cycle therapy . Treatment continue evidence continue response 8 cycle . Patients receive follow include normal laboratory evaluation least every 3 month skeletal survey perform least every 6 month .</brief_summary>
	<brief_title>A Combination Zarnestra With Velcade Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>In Phase I , patient receive intravenous PS-341 ( Velcade ) 3 different dose level oral R115777 ( Zarnestra ) . Dose Limiting Toxicity ( DLT ) determine period one cycle dose escalation next level occur patient project level complete one cycle therapy . Once DLT determine , patient Phase I patient enrol phase II component treat maximum tolerate dose ( MTD ) complete 8 cycle therapy . Treatment continue beyond 8 cycle evidence continue response . The study regimen consist two week treatment follow one week total cycle duration three week . If disease stabilization occur ( noted 2 consecutive cycle ) standard 8 cycle give , treatment discontinue . Patients monitor adverse event throughout treatment phase minimum 30 day last dose drug . Follow include history physical exam laboratory evaluation least every 3 month . Laboratories include CMP , CBC , SPEP , UPEP , quantitative immunoglobulin . A skeletal survey perform least every 6 month .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Voluntary write informed consent Female subject either postmenopausal/surgically sterilize willing use acceptable method birth control duration study . Male subject agrees use acceptable method contraception duration study . Diagnosis stage II III multiple myeloma relapse least one prior therapy confirm presence : 1 . A new lytic lesion 2 . A 25 % increase urine serum monoclonal protein Patient receive PS341 ( Velcade ) previously require previous response . Patients must measurable disease . One follow must present qualify study : 1 . Serum Mcomponent great equal 1.0 gm/dl ( 10.0 g/L ) serum protein electrophoresis 2 . Urine Mprotein excretion &gt; 200 mg/24 ( 0.2 g/24h ) hour , urine protein electrophoresis 3 . Abnormal serum free light chain ratio elevate Kappa Lambda light chain serum Baseline measurement must do within 21 day study entry . Karnofsky Performance Status Scale &gt; 60 . Greater equal 18 year age . Expected survival great 8 week . Swallow intact study medication tablet . Can follow direction caregiver responsible administer study medication . Previously treat R115777 ( Zarnestra ) . Undergone allogeneic bone marrow transplant . A platelet count &lt; 100,000 x 10 9 power/L within 14 day enrollment . Absolute neutrophil count &lt; 1.0 x 10 9 power/L within 14 day enrollment . Measured creatinine &gt; 1.5 X upper limit normal within 14 day enrollment . Greater equal Grade 2 peripheral neuropathy within 14 day enrollment . Hypersensitivity bortezomib , boron , mannitol imidazole compound Female subject pregnant breastfeeding . Confirmation subject pregnant must establish negative serum betahuman chorionic gonadotropin ( betahCG ) pregnancy test result obtain screening . Received investigational drug within 14 day enrollment immunotherapy within 30 day enrollment . Serious medical psychiatric illness likely interfere participation clinical study . Ongoing radiation therapy radiation therapy within 14 day prior first treatment . Cytotoxic chemotherapy within 30 day prior first treatment . Therapy highdose corticosteroid within 14 day prior first treatment . Presence follow excludes patient enter study condition resolve ( determine within 14 day prior first treatment ) : 1 . Elevated total bilirubin &gt; 2mg/dl , direct bilirubin &gt; 2 time ULN . 2 . Serum glutamic oxaloacetic transaminase ( AST , formerly SGOT ) serum glutamic pyruvic transaminase ( ALT , formerly SGPT ) &gt; 2 time ULN 3 . Serum calcium &gt; 12 mg/dL . 4 . Concurrent serious infection . 5 . Lifethreatening illness ( unrelated tumor ) . History ACTIVE INVASIVE cancer present condition ( except nonmelanoma skin cancer ) , unless complete remission therapy disease minimum 3 year . Prohibited/allowable medication precaution : 1 . Enzymeinducing antiepileptic medication ( e.g . phenytoin , phenobarbital , carbamazepine ) allow . 2 . Nonenzyme antiepileptic medication allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Velcade ( PS-341 )</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Zarnestra ( R115777 )</keyword>
	<keyword>Tipifarnib</keyword>
</DOC>